Hydroxyurea treatment for chronic myeloid leukemia during pregnancy

Autor:	M, Celiloglu, S, Altunyurt, B, Undar
Jazyk:	angličtina
Rok vydání:	2000
Předmět:	Adult Pregnancy Leukemia Myelogenous Chronic BCR-ABL Positive Infant Newborn Pregnancy Outcome Humans Hydroxyurea Obstetrics and Gynecology Antineoplastic Agents Female General Medicine Pregnancy Complications Neoplastic
Popis:	The incidence of chronic myeloid leukemia (CML) associated with pregnancy is estimated to be 1/75,000. Several types of treatments have been used for CML during pregnancy. These are cytotoxic drugs, alpha-interferone, splenic irradiation (with shielding of the uterus) and leukapheresis. Hydroxyurea is a cytotoxic drug that inhibits the synthesis of DNA and can be used both in the chronic and accelerated phases of CML (1).
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52216daa1b47c89d042994774ae99b1b https://avesis.deu.edu.tr/publication/details/51aec54c-6f3a-4a94-8faa-10e643ddfcd1/oai Zobrazit plný text záznamu